Antibody-drug conjugates (ADCs) exhibit high specificity and affinity towards well-defined targets, thereby enhancing the therapeutic window of the conjugated drugs (payloads). Alfa Cytology offers development services for ADCs specifically designed for bladder cancer.
Introduction to ADC
The antibody-drug conjugates (ADCs) are targeted agents that connect a cytotoxic drug, also known as a cytotoxic payload or warhead, to a monoclonal antibody via a linker. This linker enables the ADC to specifically recognize a cellular surface antigen and deliver the toxic payload directly at the tumor site. As a result, chemotherapy efficacy is enhanced while systemic exposure and toxicity are reduced.
Fig.1 Antibody-drug conjugate structure. (Hafeez, U., et al. 2020)
ADC for Bladder Cancer Therapy
A large number of ADC drugs are developed for the therapeutic use in bladder cancer.
| Drug (Target) |
Combined with (or compared to) |
Disease |
Phase |
Status |
| Disitamab |
\ |
Urothelial Carcinoma |
II |
Recruiting |
| Vedotin (HER2) |
\ |
Urothelial Carcinoma |
II |
Recruiting |
| Enfortumab Vedotin (Nectin-4) |
\ |
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial |
II |
Active, not recruiting |
| \ |
Tumors, Medical Oncology, Neoplasms |
I |
Completed |
| docetaxel, vinflunine, paclitaxel |
Ureteral Cancer, Urothelial Cancer, Bladder Cancer |
II |
Active, not recruiting |
| Pembrolizumab cisplatin, carboplatin, gemcitabine |
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms, Urothelial Cancer, Ureteral Neoplasms, Urethral Neoplasms |
I / II |
Recruiting |
| adoTrastuzumab Emtansine (HER2) |
\ |
Bladder Cancer, Pancreas Cancer, Cholangiocellula Carcinoma |
II |
Completed |
| \ |
Solid Tumor Cancers, Lung Cancer, Bladder Cancer.Urinary Tract Cancers |
II |
Active, not recruiting |
| TrastuzumabDeruxtecan (HER2) |
Nivolumab |
Breast Cancer, Urothelial Carcinoma |
I |
Recruiting |
| SacituzumabGovitecan (Trop2) |
Pembrolizumab |
Urothelial Carcinoma |
II |
Recruiting |
| Rucaparib, Lucitanib |
Ovarian Cancer, Triple-negative Breast Cancer, Urothelial, Carcinoma, Solid Tumor |
I / II |
Recruiting |
| Sirtratumab Vedotin (SLITRK6) |
\ |
Metastatic Urothelial Cancer |
I |
Completed |
Our Services
As a leading authority in the field of antibody-drug conjugate (ADC) research and development, Alfa Cytology offers comprehensive end-to-end ADC development services to facilitate the creation of highly tailored and personalized ADCs.
Antibody and Payload Selection
Precision is paramount in selecting antibodies and cytotoxic drugs for ADC development. We meticulously choose antibodies with high specificity for cancer cells while evaluating cytotoxic drugs based on potency and mechanism. Through advanced engineering, we optimize antibody-drug conjugation, enhancing tumor targeting.
Drug-Linker Technology
Leveraging cutting-edge drug-linker technologies, we facilitate the precise conjugation of cytotoxic payloads to antibodies. This sophisticated process involves the design and synthesis of linkers that enable controlled release of the payload within cancer cells, thereby maximizing therapeutic efficacy while minimizing systemic toxicity.
Preclinical Assessment and Optimization
In the process of developing ADC candidate drugs, we conduct comprehensive preclinical evaluation and optimization, including in vitro cell studies, animal model research, as well as pharmacokinetic and toxicological assessments, to ensure the safety and efficacy of the drugs.
Contact Us
The team at Alfa Cytology consists of highly skilled scientists and professionals who possess extensive expertise and technical prowess in the field of ADC development. If you are interested in our services, please contact us for more detailed information.
Reference
- Hafeez, U., Parakh, S., and et al. Antibody-Drug Conjugates for Cancer Therapy. Molecules (Basel, Switzerland), 2020, 25(20), 4764.
For research use only. Not intended for any clinical use.
Related Services
